
|Videos|April 8, 2022
Dr. Min Dong discusses next steps with therapeutic toxins for urologic disease
Author(s)Urology Times staff
“We are not just changing toxins for the sake of changing toxins; we are changing toxins to satisfy the needs from the clinical community,” says Min Dong, MD.
Advertisement
In this video, Min Dong, MD,summarizes the main points of his talk, “New frontiers in therapeutic toxins for urologic disease,” which was presented at the Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction 2022 Winter Meeting. Dong is an associate professor of Urology at Harvard Medical School in Cambridge, Massachusetts.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves lutetium Lu 177 vipivotide tetraxetan for PSMA-positive mHSPC
2
Testosterone deficiency: FAQs from the AUA guideline
3
Joshua Lang, MD, MS, on integrating molecular biomarkers into clinical practice
4
Large registry study reports durable 10-year outcomes with focal therapy for prostate cancer
5












